Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|36|6|342-347

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.36, Iss.6, 2013-04, pp. : 342-347

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

John Wiley & Sons Inc

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 681-684

Karger

Access to resources Recommend Favorite

Chemotherapy in Elderly Patients with Advanced Lung Cancer Part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 27, Iss. 6, 2004-12 ,pp. : 583-588

Karger

Access to resources Recommend Favorite